Breast Cancer Screening Now Starts at 40: What the Updated USPSTF Guidance Means for Women

What Changed in 2024—and Who It Applies To

Most women in the United States should now start routine mammograms at age 40.

In 2024, the U.S. Preventive Services Task Force (USPSTF) updated its breast cancer screening recommendation to advise biennial (every two years) mammography for women ages 40 to 74. The recommendation carries a Grade B rating, meaning the Task Force found moderate certainty that screening provides a moderate net benefit.

This replaces the previous guidance, which started routine screening at age 50 for women at average risk.

The recommendation applies to women who are at average risk for breast cancer. It does not apply to women with known BRCA1 or BRCA2 genetic mutations, a strong family history of breast cancer, prior chest radiation at a young age, or certain high-risk breast lesions. Those women may need earlier or more intensive screening and should have individualized plans.

Why the USPSTF Lowered the Starting Age to 40

The USPSTF based its update on a new systematic evidence review and modeling studies published alongside the recommendation in JAMA.

Unlike earlier screening debates that relied heavily on older randomized clinical trials, the current update leaned on:

A comprehensive review of existing studies
Statistical modeling that estimated benefits and harms using modern breast cancer data
Updated information about breast cancer incidence and mortality trends

According to the Task Force, breast cancer incidence among women in their 40s has increased in recent years. At the same time, modeling suggested that starting screening at 40 instead of 50 would prevent additional breast cancer deaths at the population level.

It is important to understand that the evidence for women ages 40–49 includes limited modern randomized trial data. Much of the projected benefit comes from modeling studies that simulate outcomes using current treatment patterns and cancer rates. Modeling is a standard tool in public health policy, but it depends on assumptions and cannot perfectly predict real-world outcomes.

What the Evidence Shows: Benefits and Limits

Breast cancer is the second leading cause of cancer death among women in the United States, according to the Centers for Disease Control and Prevention (CDC). Earlier detection can improve treatment options and survival.

The updated evidence review found that starting biennial screening at 40 rather than 50 is expected to:

Prevent more breast cancer deaths across the population
Detect cancers at earlier stages

However, the reduction in mortality is considered modest in absolute terms. Screening lowers risk; it does not eliminate it. And not every cancer found early would have become life-threatening.

That balance between benefit and harm is central to the recommendation.

Potential Harms: False Positives, Overdiagnosis, and Anxiety

Screening is not risk-free. The JAMA evidence review emphasized several tradeoffs:

False positives: Mammograms sometimes suggest cancer when none is present. This can lead to additional imaging or biopsies.
Overdiagnosis: Some cancers detected through screening may grow so slowly that they would never cause symptoms or death. Because we cannot reliably tell which ones these are, most are treated.
Psychological stress: Waiting for follow-up tests can cause significant anxiety.

Starting screening at 40 increases the total number of mammograms a woman receives over her lifetime, which increases the chance of experiencing at least one false alarm.

The USPSTF concluded that, for average-risk women, the benefits outweigh these harms—but the harms are real and should be part of shared decision-making.

Dense Breasts and Supplemental Imaging: What We Know and Don’t Know

Breast density is common, especially in younger women. Dense breast tissue can:

Make mammograms harder to interpret
Increase the risk of breast cancer

The USPSTF found that there is currently insufficient evidence to recommend for or against routine supplemental screening (such as ultrasound or MRI) for women with dense breasts who are otherwise at average risk.

That means there is uncertainty—not that supplemental screening is ineffective, but that evidence is not strong enough yet to make a universal recommendation.

If you have dense breasts, ask your clinician about your overall risk profile and whether additional imaging makes sense in your situation.

Racial Disparities and Why They Matter

Breast cancer does not affect all women equally.

Black women in the United States are more likely to die from breast cancer than white women, even though incidence rates are similar. According to the USPSTF and CDC data, disparities are driven by multiple factors, including differences in tumor biology, stage at diagnosis, access to care, and systemic inequities.

The Task Force noted that beginning screening at 40 may help narrow mortality gaps, particularly because Black women are more likely to be diagnosed at younger ages. However, screening alone will not eliminate disparities. Access to timely follow-up, high-quality treatment, insurance coverage, and structural equity all play roles.

Insurance Coverage Under the ACA: What Women Can Expect

Under the Affordable Care Act (ACA), most private insurance plans are required to cover preventive services that receive a USPSTF Grade A or B recommendation without cost-sharing when delivered in-network.

Because the updated breast cancer screening recommendation carries a Grade B rating, most insured women can expect screening mammograms to be covered without a copay or deductible when they follow the recommended schedule.

However, some plans—such as certain grandfathered plans—may not be subject to the same requirements. It is wise to confirm coverage with your insurer before scheduling.

Who Is Considered Average Risk?

This recommendation applies to women who:

Have no personal history of breast cancer
Do not carry known high-risk genetic mutations like BRCA1 or BRCA2
Have not had chest radiation at a young age
Do not have a strong family history that significantly elevates risk

If you fall into a higher-risk category, you may need earlier screening, annual screening, breast MRI, or genetic counseling. Professional organizations such as the American College of Obstetricians and Gynecologists (ACOG) emphasize individualized risk assessment.

Questions to Ask Your Clinician at 40

Am I considered average risk, or do I need a different screening plan?
How often should I schedule mammograms?
Do I have dense breasts, and how does that affect my risk?
What should I expect if a mammogram result is abnormal?
Will my insurance fully cover this screening?

What This Means for Women

For most women in the United States, the practical takeaway is straightforward:

Plan to start mammograms at age 40.
Repeat screening every two years through age 74, unless your clinician recommends otherwise.
Understand that screening reduces—but does not eliminate—your risk of dying from breast cancer.
Be prepared for the possibility of false alarms.
Discuss personal risk factors and breast density with your healthcare provider.

This is not a dramatic shift in technology or treatment. It is an evidence-based policy adjustment aimed at modestly reducing breast cancer deaths while acknowledging tradeoffs. Shared decision-making remains central, especially for women with family history, dense breasts, or prior abnormal results.

If you are approaching 40—or have recently turned 40—now is a good time to start that conversation.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.